Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.

Autor: Bachelot, Thomas, Cottu, Paul, Chabaud, Sylvie, Dalenc, Florence, Allouache, Djelila, Delaloge, Suzette, Jacquin, Jean-Philippe, Grenier, Julien, Venat Bouvet, Laurence, Jegannathen, Apurna, Campone, Mario, Del Piano, Francesco, Debled, Marc, Hardy-Bessard, Anne-Claire, Giacchetti, Sylvie, Mouret-Reynier, Marie-Ange, Barthelemy, Philippe, Kaluzinski, Laure, Mailliez, Audrey, Legouffe, Eric
Zdroj: Journal of Clinical Oncology; 11/10/2022, Vol. 40 Issue 32, p3699-3708, 10p
Databáze: Supplemental Index